Table 4 Univariate and multivariate analysis of factors associated with overall survival and progression-free survival

 Age (< 65 years/≥ 65 years)

4.541 (1.694–12.172)

0.003

2.414 (1.033–5.641)

 Gender (male/female)

0.841 (0.319–2.219)

0.727

0.689 (0.283–1.681)

 Location (upper/middle/lower)

0.812 (0.437–1.508)

0.509

0.710 (0.401–1.256)

 Length (< 5 cm/≥ 5 cm)

1.905 (0.773–4.697)

0.161

1.814 (0.807–4.078)

 Clinical stage (IIb/III)

2.975 (0.982–9.015)

0.054

2.405 (0.932–6.206)

 Response (OR/non-OR)

2.442 (0.973–6.126)

0.057

2.587 (1.096–6.109)

 BF

1.983 (0.811–4.852)

0.134

1.821 (0.787–4.214)

 BV

1.181 (0.489–2.853)

0.712

1.234 (0.552–2.762)

 TTP

1.507 (0.631–3.600)

0.335

1.681 (0.725–3.898)

 SUVmax

1.088 (0.458–2.587)

0.848

1.240 (0.555–2.769)

 MTV

1.308 (0.554–3.088)

0.540

1.780 (0.761–4.162)

 TLG

1.308 (0.554–3.088)

0.540

1.780 (0.761–4.162)

 FMR

3.092 (1.245–7.678)

0.015

2.829 (1.202–6.661)

 Age(< 65 years/≥ 65 years)

7.446 (2.273–24.395)

0.001

2.592 (1.081–6.213)

 Clinical stage (IIb/III)

3.790 (1.104–13.013)

0.034

NA

 Response (OR/non-OR)

NA

0.867

NA

 FMR

2.914 (1.138–7.462)

0.026

3.009 (1.252–7.227)